Navigation Links
CRF announces late breaking trials and first report investigations to be presented at TCT 2013
Date:9/20/2013

NEW YORK, NY September 20, 2013 The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 28 November 1, 2013 at The Moscone Center in San Francisco, California.

Clinical trial data and first report investigations presented at TCT often direct the course of patient therapies. The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Tuesday, October 29; Wednesday, October 30; and Thursday, October 31.

This year, TCT will also mark 25 years of innovation with a day-long look back at the significant contributions that interventional cardiology has made to patients with cardiovascular disease, as well as an inspiring look ahead at new therapies being developed for the not too distant future.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.tctconference.com/press/press-registration-form.html

TUESDAY OCTOBER 29, 2013
Late Breaking Trials

  • SAFE-PCI: A Prospective, Registry-Based Randomized Trial of Radial Versus Femoral Vascular Access in Women Undergoing Diagnostic Cardiac Catheterization and PCI

  • COREVALVE EXTREME RISK: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Self-Expanding Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

  • SORT-OUT VI: A Prospective, Randomized "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents Versus Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary Stents

WEDNESDAY, OCTOBER 30, 2013
Late Breaking Trials

  • EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin Versus Heparin Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI Undergoing Primary PCI

  • NORDIC-BALTIC BIFURCATION IV: A Prospective, Randomized Trial of a Two-Stent Strategy Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions

  • TRYTON: A Prospective, Randomized Trial of a Dedicated Sidebranch Stent Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions

First Report Investigations

  • LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

  • RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Versus Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

  • SMART-CASE: A Prospective, Randomized Trial of Conservative Revascularization Versus Aggressive Revascularization in Patients with Intermediate Lesions Undergoing PCI with Angiographic Guidance Alone

  • HeartFlowNXT: A Prospective, Registry Evaluation of Noninvasive FFRCT Versus Invasive FFR

  • ADVISE II: A Prospective, Registry Evaluation of iFR Versus FFR CHILL-MI: A Prospective, Randomized Trial of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction Undergoing Primary PCI

THURSDAY, OCTOBER 31, 2013
Late Breaking Trials

  • OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy After PCI

  • ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of 2 Years Versus 1 Year of Dual Antiplatelet Therapy After PCI

  • DUTCH PEERS (TWENTE II): A Prospective, Randomized "All-Comers" Trial of Zotarolimus-Eluting Stents Versus Everolimus-Eluting Coronary Stents

First Report Investigations

  • REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

  • FREEDOM: A Prospective, Randomized Trial of First Generation DES Versus CABG in Insulin and Non-Insulin Treated Diabetic Patients

  • HYBRID: A Prospective, Randomized Trial of Hybrid Coronary Revascularization Versus Standard Surgical Revascularization in Multivessel Disease

  • TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI

  • GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

  • TATORT-NSTEMI: A Prospective, Randomized Trial of Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Segment Elevation Myocardial Infarction


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. National Personal Training Institute Announces Two New Locations in Pittsburgh and New York City
2. Baron and Budd Announces Second Transvaginal Mesh Lawsuit Settlement for Bard
3. 360Websitedesign Announces Website Maintenance Services
4. ELK Consulting announces their new editing service
5. Zion Health Announces Native Remedy; Ancient Clay Soaps for Sensitive Skin; New Addition to Whole Foods Market Body Care in Andover, MA
6. Heroes in Recovery Announces Second Annual Race in Roswell, Georgia
7. Fitness 19 Announces the Opening of the Newbury Park, CA Location
8. CBT News Announces In-Depth Coverage of NADA Convention in New Orleans
9. HMP Communications Holdings, LLC Announces Launch of Interventional Oncology 360
10. The Art of Living TV Show Announces 2013 Telly Award Honors for DC’s Wine Country - Visit Loudoun Segment
11. Online USA Doctors Announces a New Online, Medical Record System That Improves Patient Health Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Southlake, Texas (PRWEB) , ... March 24, 2017 ... ... make 2017 the year of enhancements, upgrading their training and leads programs. , ... Empower University. Reserved for elite sales agents, Performance Partners is designed to teach ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks ... lives his life to the fullest, as God intended. “The Adventures of Joey, The ... mother and grandmother pursuing her passion for writing, especially about truth and human behavior. ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from ... into teacher preparation programs. The NCTQ report suggests, based on a review of GPA ... significantly improve teacher quality in the U.S. It argues that this higher bar should ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017  Zymo ... company, and Hamilton Robotics, Inc., who designs, ... an ongoing collaboration that teams Zymo Research,s ... RNA and DNA extraction products with Hamilton,s ... created optimized methods for microbiomics and RNA ...
(Date:3/24/2017)... March 24, 2017   The Accreditation Council ... medical affairs in the pharmaceutical industry has appointed ... of a newly formed scientific advisory board. Dr. ... form the first ever medical affairs think tank ... information about the ACMA, please visit  www.medicalaffairsspecialist.org .  ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: